Should not we vaccinate the public against seasonal influenza all over the year in COVID-19 era?

Should not we vaccinate the public against seasonal influenza all over the year in COVID-19 era?

Mohamed Farouk Allam (1,2,3)* and Khaled Mahmoud Abd-Elaziz (2)

1. Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

2. Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

3. Department of Community Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

 

Current Research in Public Health 2023:3(2):44–46.

DOI: 10.31586/crph.2023.706

ABSTRACT

The pandemic of the SARS-CoV2 (COVID-19) that was declared by the World Health Organization (WHO) on 11 March 2020 is still ongoing. One of the early recommendations from CDC and other international agencies is the seasonal influenza vaccination to decrease the effects and burden of COVID-19 pandemic. This review suggests that during COVID-19 pandemic vaccination against seasonal influenza should be conducted all over the year, even for young age groups, because of several reasons. First, the complications of seasonal influenza, especially pneumonia, could increase the burden on the saturated healthcare systems worldwide. Second, the resemblance of symptoms and signs of both seasonal influenza and COVID-19 will difficult diagnosing and isolation of COVID-19 patients. Third, it has been postulated that there is a cross immunity between seasonal influenza and COVID-19.

 

Keywords: Coronavirus, COVID-19, Influenza, Vaccine, Review.

 

Current Research in Public Health 2023.

https://www.scipublications.com/journal/index.php/CRPH/article/view/706

New Topical Treatment for Psoriasis

New Topical Treatment for Psoriasis

Jose Miguel Ingelmo Calvo (1), José Ruiz Cobo (2) and Mohamed Farouk Allam (3*)

1. Department of Plastic Surgery, Hospital HM Malaga, Malaga, Spain;

2. Distrito Sanitario Costa del Sol, SUAP Torremolinos, Malaga, Spain;

3. Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

 

Journal of Exploratory Research in Pharmacology 2023

 

DOI: 10.14218/JERP.2023.00015

 

Abstract

Topical corticosteroids, alone or in combination with calcipotriol, a topical vitamin D analog, have proved effective in treating mild to moderate psoriasis. Topical corticosteroids, like clobetasol propionate, have a vasoconstrictor effect on the peripheral dermal vessels, and this explains skin atrophy in psoriatic patients applying topical corticosteroids regularly for long periods. However, a new topical treatment for psoriasis has been developed and patented. The new treatment is prepared as a lotion and is composed of clobetasol, papaverine hydrochloride, spironolactone, milk-peptide-complex, and propylene glycol. A 47-year-old male presented with extensive psoriasis lesions in the elbows and back. The patient had an irrelevant past medical history and was complaining mainly of severe itching in the psoriatic lesions. The patient was advised to use our newly patented lotion once daily for one week. After 7 days of local application of the new lotion, the patient was examined in the outpatient clinic. The patient reported significant improvement in the itching sensations and remission of the scaled lesions. Comparing the lesions before and after the application of the local treatment for 7 days, it was observed that the psoriasis area severity index score had improved from 20.9 to 1.8. Further studies with larger sample sizes and longer follow-up periods are required to confirm the findings of our case report.

 

Keywords: Psoriasis; Topical treatment; Psoriasis area severity index; Malaga.

 

Journal of Exploratory Research in Pharmacology 2023

 

https://www.xiahepublishing.com/2572-5505/JERP-2023-00015

https://www.xiahepublishing.com/2572-5505/JERP-2023-00015/pdf